The trajectory for repeat expansion in the Huntington's disease brain is not understood and these results indicate that the greatest benefit for MSH3-targeting therapeutics will be realized by treating as early as possible before cell-specific pathogenic thresholds have been achieved. The gene discussed is MSH3; the disease is juvenile Huntington disease.